Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access ProgramSusan E. Prockop, Sarah Nikiforow, Rolla Abu‐Arja et al.|Blood|2019Cited by 9
Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program StudySusan E. Prockop, Sarah Nikiforow, Ran Reshef et al.|Transplantation and Cellular Therapy|2020Cited by 3